Metformin-induced AMPK activation stimulates remyelination through induction of neurotrophic factors, downregulation of NogoA and recruitment of Olig2+ precursor cells in the cuprizone murine model of multiple sclerosis.
AMP-Activated Protein Kinases
/ genetics
Animals
Cuprizone
/ adverse effects
Disease Models, Animal
Down-Regulation
Enzyme Activation
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Male
Metformin
/ administration & dosage
Mice
Mice, Inbred C57BL
Multiple Sclerosis
/ chemically induced
Nerve Growth Factors
/ genetics
Oligodendrocyte Transcription Factor 2
/ genetics
AMPK
Cuprizone
Metformin
Multiple sclerosis
Remyelination
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
17
10
2018
accepted:
30
06
2019
pubmed:
18
10
2019
medline:
10
4
2020
entrez:
18
10
2019
Statut:
ppublish
Résumé
Oligodendrocytes (OLGs) damage and myelin distraction is considered as a critical step in many neurological disorders especially multiple sclerosis (MS). Cuprizone (cup) animal model of MS targets OLGs degeneration and frequently used to the mechanistic understanding of de- and remyelination. The aim of this study was exploring the effects of metformin on the OLGs regeneration, myelin repair and profile of neurotrophic factors in the mice brain after cup-induced acute demyelination. Mice (C57BL/6 J) were fed with chow containing 0.2% cup for 5 weeks to induce specific OLGs degeneration and acute demyelination. Next, the cup was withdrawn to allow one-week recovery (spontaneous remyelination). At the end of this period, mature OLGs markers, myelin-associated neurite outgrowth inhibitor protein A (NogoA), premature specific OLGs transcription factor (Olig2), anti-apoptosis marker (survivin), neurotrophic factors, and AMPK activation were monitored in the presence or absence of metformin (50 mg/kg body weight/day) in the corpus callosum (CC). Our finding indicated that consumption of metformin during the recovery period potentially induced an active form of AMPK (p-AMPK) and promoted repopulation of mature OLGs (MOG This study for the first time reveals that metformin-induced AMPK, a master regulator of energy homeostasis, activation following toxic demyelination could potentially accelerate regeneration and supports spontaneous demyelination. These findings suggest the development of new therapeutic strategies based on AMPK activation for MS in the near future. Graphical abstract An overview of the possible molecular mechanisms of action of metformin-mediated remyelinationa.
Identifiants
pubmed: 31620963
doi: 10.1007/s40199-019-00286-z
pii: 10.1007/s40199-019-00286-z
pmc: PMC6895294
doi:
Substances chimiques
Nerve Growth Factors
0
Olig2 protein, mouse
0
Oligodendrocyte Transcription Factor 2
0
Cuprizone
5N16U7E0AO
Metformin
9100L32L2N
AMP-Activated Protein Kinases
EC 2.7.11.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-592Subventions
Organisme : Shahrekord University of Medical Sciences
ID : 1393-01-87-2325
Organisme : University of Zabol
ID : 9618-5
Références
CNS Drugs. 2017 Mar;31(3):187-198
pubmed: 28105588
CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1242-56
pubmed: 23844684
Cereb Cortex. 2018 Jun 1;28(6):2109-2117
pubmed: 28505229
Kaohsiung J Med Sci. 2014 May;30(5):235-42
pubmed: 24751386
Nat Commun. 2013;4:2192
pubmed: 23900241
J Neurosci. 2011 Oct 5;31(40):14182-90
pubmed: 21976503
Pharm Biol. 2017 Dec;55(1):1679-1687
pubmed: 28447514
Neurochem Res. 2015 Sep;40(9):1767-85
pubmed: 26266872
Cytokine Growth Factor Rev. 2015 Oct;26(5):507-15
pubmed: 26187860
Riv Psichiatr. 2009 Mar-Apr;44(2):79-87
pubmed: 20066808
Metab Brain Dis. 2018 Feb;33(1):107-114
pubmed: 29080083
J Neurosci. 2013 Feb 13;33(7):3240-50
pubmed: 23407977
Neurosignals. 2010;18(3):186-202
pubmed: 21242670
Brain. 2010 Aug;133(Pt 8):2248-63
pubmed: 20826430
Neuro Endocrinol Lett. 2015;36(2):148-52
pubmed: 26071584
J Neurosci. 2002 Nov 1;22(21):9221-7
pubmed: 12417647
Adv Biomed Res. 2015 Feb 17;4:53
pubmed: 25802822
Eurasian J Med. 2011 Dec;43(3):141-5
pubmed: 25610182
Neuroscientist. 2013 Aug;19(4):394-408
pubmed: 23423307
Ann Neurol. 2010 Apr;67(4):498-507
pubmed: 20437585
Pharm Biol. 2016 Oct;54(10):2211-9
pubmed: 26960058
Dev Neurobiol. 2018 Feb;78(2):123-135
pubmed: 28986960
Oncol Lett. 2016 Sep;12(3):1679-1686
pubmed: 27588117
Metab Brain Dis. 2018 Feb;33(1):27-37
pubmed: 29022246
Neuroscience. 2014 Sep 26;277:747-54
pubmed: 25108167
Phytother Res. 2019 May;33(5):1363-1373
pubmed: 30864249
Toxicol Appl Pharmacol. 2018 Mar 1;342:86-98
pubmed: 29407366
J Neurosci. 2010 Feb 24;30(8):2989-3001
pubmed: 20181596
Nat Med. 2002 Jun;8(6):620-4
pubmed: 12042814
JAMA Neurol. 2016 May 1;73(5):520-8
pubmed: 26953870
Am J Pathol. 2006 Aug;169(2):584-98
pubmed: 16877358
Biol Trace Elem Res. 2018 Aug;184(2):422-435
pubmed: 29189995
Cancer Res. 2007 Jul 15;67(14):6745-52
pubmed: 17638885
Curr Drug Targets. 2017;18(13):1499-1517
pubmed: 27829351
BMC Complement Altern Med. 2017 May 2;17(1):240
pubmed: 28464811
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:49-61
pubmed: 29203302
Sci Rep. 2017 Sep 21;7(1):12119
pubmed: 28935984
Mol Neurobiol. 2016 Mar;53(2):1092-1107
pubmed: 25579386
Br J Pharmacol. 2014 Jul;171(13):3146-57
pubmed: 24611741
Cell Mol Biol (Noisy-le-grand). 2016 Oct 31;62(12):24-30
pubmed: 27894396
J Immunol. 2009 Jun 15;182(12):8005-14
pubmed: 19494326
Acta Neuropathol. 2017 Sep;134(3):423-440
pubmed: 28646336
Cell Stem Cell. 2012 Jul 6;11(1):23-35
pubmed: 22770240
Neurosci Biobehav Rev. 2014 Nov;47:485-505
pubmed: 25445182
J Neurosci. 2014 Jun 11;34(24):8186-96
pubmed: 24920623
Int J Mol Sci. 2017 Apr 20;18(4):null
pubmed: 28425952
Front Neuroanat. 2016 May 09;10:50
pubmed: 27242448
J Neurosci. 2005 Aug 31;25(35):7924-33
pubmed: 16135749
Am J Pathol. 2013 Aug;183(2):526-41
pubmed: 23759513